T-cell large granular lymphocytic (T-LGL) leukemia after hematopoietic stem cell transplantation (SCT) is rare and its natural history and clinical outcome have not been well described. We report the clinical, morphologic, immunophenotypic, and molecular features of a case of donor-derived T-LGL leukemia in a 16-year-old man who received allogeneic SCT for peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). The patient presented with persistent neutropenia and splenomegaly 9 months after SCT when the chimerism study showed a 100% donor pattern. A splenectomy revealed T-LGL leukemia. Flow cytometric analysis showed an aberrant T-cell population positive for CD3, CD5 (dim, subset), CD7, CD8, CD16 (subset), CD57, CD94 (dim, partial), and T-cell receptor (TCR) αβ, and negative for CD4, CD26, CD56, and TCRγδ. Molecular studies showed monoclonal TCRβ and TCRγ gene rearrangements. Both the immunophenotype and molecular profile of the T-LGL leukemia were different from the pre-SCT PTCL. Sequencing analysis for STAT3 exon 21 did not reveal any mutation in both pre-SCT and post-SCT specimens. The patient did not receive any treatment for T-LGL leukemia; however, his count progressively increased after splenectomy, despite the presence of persistent T-LGL leukemia in the bone marrow. There was no evidence of recurrent PTCL. We propose an algorithm to diagnose this rare post-SCT neoplasm.
Donor-Derived T-Cell Large Granular Lymphocytic Leukemia in a Patient
LGL proliferation has been observed after allogeneic and autologous hematopoietic stem cell transplantation (SCT). [3] [4] [5] [6] The expanded T-LGLs are usually polyclonal or oligoclonal. Rare cases of T-LGL leukemia have also been reported after hematopoietic SCT, [7] [8] [9] [10] [11] [12] with a frequency of 0.5%. 12 Whereas most patients with T-LGL leukemia occurring in the post-SCT setting had remained asymptomatic with stable LGL counts and did not require specific treatment, 9, 12 rare patients have been reported with an aggressive clinical course with progressive pancytopenia and death in a short interval. 
T-cell large granular lymphocytic (T-LGL) leukemia
is an indolent neoplasm characterized by a persistent (>6 months) increase in peripheral blood LGLs, usually between 2 and 20 x 10 9 /L. 1 Patients often present with neutropenia, splenomegaly, and autoimmune disorders. The LGLs are typically cytotoxic T cells expressing CD3, CD8, and T-cell receptor (TCR) αβ, with monoclonal TCR gene rearrangements. The pathogenesis of T-LGL leukemia is not well defined. However, chronic antigenic stimulation has been suggested as one underlying mechanism because of the frequent association between T-LGL leukemia and autoimmune disorders.
We report a case of a young patient with a history of peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) who developed T-LGL leukemia of donor origin after allogeneic SCT, with a comprehensive literature review. A diagnostic algorithm to distinguish T-LGL leukemia and T-LGL proliferation and other lymphoproliferative disorders after SCT is proposed.
Case Report
A 16-year-old man initially presented to another hospital with fever, weight loss, lymphadenopathy, and hepatosplenomegaly in October 2012. A diagnosis of PTCL-NOS was established based on an inguinal lymph node (LN) biopsy. He came to our hospital for a second opinion and treatment options, where we confirmed the diagnosis of PTCL-NOS associated with hemophagocytosis and bone marrow (BM) involvement. He received dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) for 6 cycles beginning in January 2013. At the end of this regimen, PET scan showed increased FDG activity in the spleen. He was then treated with 2 cycles of cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP) followed by 2 cycles of gemcitabine and 2 doses of romidepsin due to persistent disease in the BM. At this time, he received 2 cycles of alemtuzumab with a reduction of tumor burden in the BM (partial response). On June 4, 2014, he received allogeneic SCT from his brother with gemcitabine, clofarabine, and busulfan. Unfortunately, he developed primary graft failure. He then received a second transplant from his brother using fludarabine, antithymocyte globulin (ATG), and a higher CD34 cell dose in July 2014, which was successfully engrafted as shown by 100% T cells and myeloid cells of donor origin on microsatellite polymorphism analysis. He experienced complete remission of PTCL.
Three months later, his clinical course was complicated by Epstein-Barr virus (EBV)-positive posttransplant lymphoproliferative disorders (PTLD) in the duodenum and supraclavicular LN that were treated with rituximab and resulted in complete remission. However, he remained pancytopenic and did not respond to granulocyte colony-stimulating factor and was not explained by viral infection (negative EBV and cytomegalovirus [CMV] by PCR), medication, chimerism status (100% engraftment), or BM involvement by neoplasm. A CBC count showed a WBC of 3.1 K/mcL (reference range, 5.1-15.5 K/mcL), hemoglobin level of 10 g/dL (reference range, 9.5-14.8 g/dL), and platelet count of 21 K/mcL (reference range, 159-353 K/mcL), with a differential count of 12% neutrophils (absolute neutrophil count, 0.37 K/mcL; reference range, 1.70-7.30 K/mcL), 73% lymphocytes (absolute lymphocyte count, 2.25 K/mcL; reference range, 1.00-4.80 K/mcL), 9% monocytes, 2% eosinophils, 2% metamyelocytes, and 2% blasts. The serum lactate dehydrogenase level was 496 IU/L (reference range, 313-618 IU/L). b 2 -microglobulin was not assessed. In addition, PET scan showed splenomegaly without increased FDG uptake. Therefore, spleen sequestration was thought to be the cause of pancytopenia. In April 2015, a splenectomy was performed, which revealed T-LGL leukemia. At this time, the patient was negative for cytomegalovirus (CMV) or EBV infection by PCR. No evidence of graft-versus-host disease (GVHD) was present. He did not receive any treatment for T-LGL leukemia; however, his WBC progressively increased to above normal, despite the presence of persistent T-LGL leukemia in the BM. At the last follow-up, 7 months after splenectomy, a CBC showed a WBC of 16.2 K/mcL, hemoglobin level of 13.8 g/dL, and platelet count of 405 K/mcL, with persistent T-LGL leukemia in the BM and peripheral blood. There was no evidence of recurrent PTCL or PTLD. The clinical course is summarized in Figure 1 .
Morphologic and Immunophenotypic Findings
Histologic sections of the initial inguinal LN biopsy showed altered LN architecture with regressed follicles. The paracortex was expanded by atypical cells with variable size, irregular nuclear contours, coarse chromatin, occasional conspicuous nucleoli, and moderate amount of cytoplasm. Immunostains revealed that the atypical cells were mainly CD3+ T cells with decreased CD7 expression. A BM biopsy showed an atypical interstitial lymphoid infiltrate composed predominantly of small to intermediatesized cells positive for granzyme B and TIA-1, supporting a diagnosis of PTCL-NOS (Figure 2A-C) . In situ hybridization for EBV-encoded small RNA (EBER) was negative. Flow cytometric analysis of the pretransplant BM showed an aberrant T-cell population positive for CD2, CD3, CD5 (subset), CD8, CD26, CD57 (partial), and TCRab, and negative for CD4, CD7, CD16, CD56, CD94, and TCRgd ( Figure 2D-F The spleen showed expanded red pulp infiltrated by numerous small lymphoid cells with hyperchromatic nuclei and moderate to abundant cytoplasm positive for CD3, granzyme B, and TIA-1 ( Figure 3A-C) . Flow cytometric analysis of the spleen and a subsequent BM showed an aberrant T-cell population positive for CD2, CD3, CD5 (dim, subset), CD7, CD8, CD16 (subset), CD57, CD94 (dim, partial), and TCRab, and negative for CD4, CD10, CD25, CD26, CD56, and TCRgd, consistent with T-LGLs ( Figure 3D-F) . This immunophenotype differed from the pretransplant PTCL in the expression of CD7, CD16, CD26, CD57, and CD94. Interestingly, a retrospective review of the flow cytometry result from the supraclavicular LN revealed a small population of aberrant T-LGLs with the same immunophenotype, suggesting that, in addition to PTLD, this LN was also involved by T-LGL leukemia.
Molecular and Cytogenetic Findings
Molecular studies using PCR/capillary electrophoresis of a pretransplant BM demonstrated monoclonal TCRg and TCRβ rearrangements, with clonal peaks at sizes 146 and 179 for TCRg, and 260 for TCRβ. Molecular analysis of the spleen also showed monoclonal TCRg and TCRβ rearrangements; however, the predominant clonal peaks were 172 for TCRg and 250 for TCRβ (Figure 4 ). In accordance with flow cytometry findings, we retrospectively detected a low-level TCRg peak with size 172 and TCRβ peak with size 250 in the supraclavicular LN specimen. We performed mutation analysis for STAT3 exon 21 using PCR/Sanger sequencing on 4 specimens: a pre-SCT BM (involved by PTCL), a post-SCT LN, spleen, and BM (involved by T-LGL leukemia). However, no mutation was detected in any of the 4 specimens (see supplementary eAppendix 1, available with this article at JNCCN.org).
Conventional cytogenetic analyses of a pretransplant BM and the posttransplant spleen and BM showed a normal diploid karyotype, 46,XY [20] .
Discussion
Expansion of T-LGLs after hematopoietic SCT has been well described. Most of these T-LGLs are reactive in nature with a self-limiting clinical course and patients are usually asymptomatic. [3] [4] [5] [6] However, rare cases of T-LGL leukemia after hematopoietic SCT have been reported in single case reports [7] [8] [9] [10] [11] or small case series. 12 Gill et al 12 reported 7 cases of T-LGL leukemia among 1,675 consecutive cases of allogeneic and autologous hematopoietic SCT in a 20-year period, representing a frequency of 0.5%. These authors suggested that T-LGL leukemia in posttransplant patients may have a different clinical course and pathogenesis compared with de novo T-LGL leukemia. Patients often remained stable for years and did not require specific treatment. 12 The pathogenesis of T-LGL expansion and leukemia is not well understood. Most studies have suggested a causal relation to chronic antigenic stimulation due to viral infection, autoimmune diseases, GVHD, or immunosuppression with decreased immunosurveillance, leading to T-LGL proliferation or neoplastic transformation. 5, 6, 13 Kim et al 6 reported a strong association of LGL lymphocytosis with chronic GVHD, pretransplant CMV status of the recipient, and CMV antigenemia. Mohty et al 4 reported that T-LGL proliferations occurred more frequently after a reduced fludarabine and ATG-based preparative regimen, because high immunosuppression of the host's immunity may lead to a state of immune balance favorable to the emergence of specific T subsets, such as LGL. Similarly, our patient received fludarabine and an ATG-based preparative regimen for his SCT. Furthermore, it has been reported that T-LGL lymphocytosis in the post-SCT setting is associated with better overall survival and lower rate of disease relapse, suggesting that T-LGL might be a subset of effector lymphocytes that may contribute to the graft-versus-tumor effect. 4, 6 The patient was negative for CMV at the time of the development of T-LGL leukemia. He did not have GVHD. However, his CMV IgG antibodies were positive in the pre-SCT workup. This finding is in keeping with the hypothesis that the T-LGL proliferation could be related to CMV in the context of chronic antigen stimulation.
Recently, somatic mutations of STAT3 have been described in 40% to 70% cases of T-LGL leukemia. 14, 15 These mutations occur at the Src homology 2 (SH2) domain of STAT3, which mediates dimerization and activation of the STAT3 protein, suggesting that aberrant STAT3 signaling underlies the pathogenesis of this disease.
14 STAT3 mutations constitutively activate the transcription of a STAT3 isoform, which is responsible for IL-6-dependent T-cell proliferation, and upregulate the downstream target genes of the STAT3 pathway, including IFNGR2, BCL2L1, and JAK2. STAT3 mutations are associated with increased phosphorylated STAT3 protein, which can be visualized by immunohistochemistry. More recently, Liang et al 16 showed that phosphorylated STAT3 was expressed in hematopoietic SCT-associated T-LGL leukemia by immunohistochemistry. As a result, specific STAT3 inhibitors have been evaluated as a novel therapeutic regimen for the treatment of T-LGL leukemia. 17 Determination of the actual frequency of T-LGL leukemia in the post-hematopoietic SCT setting has been challenged by the difficulty in the differential diagnoses between T-LGL proliferation and T-LGL leukemia. The published literature needs to be carefully reviewed because of the heterogeneity in terminology and diagnostic criteria. One study reported a frequency of 0.5%. 12 Patients with T-LGL proliferation are usually asymptomatic and have disease that is transient, nonprogressive, selflimiting, and polyclonal or oligoclonal, whereas patients with T-LGL leukemia usually have a persistently increased number of T-LGLs with immunophenotypic aberrancy and monoclonal TCR rearrangements, and have the typical manifestations of T-LGL leukemia with cytopenia, recurrent infections, autoimmune disorders, and splenomegaly. Other causes of cytopenia in the post-SCT setting, such as transplant-related causes (graft failure, poor engraftment, GVHD), infections (CMV, EBV), medications (ganciclovir), and relapse of initial disease, also need to be considered. Recently, a high level of STAT3 mutation has been shown to have diagnostic value in distinguishing T-LGL leukemia from other mature T-cell neoplasms and reactive conditions. We did not detect any mutation in exon 21 of the STAT3 gene in this case. Nevertheless, the morphologic, immunophenotypic, and molecular findings support a diagnosis of T-LGL leukemia.
The current case report complements the few reports of T-LGL leukemia in the post-SCT setting reported previously. The morphologic features of T-LGL leukemia can be subtle, and the cytopenia accompanying T-LGL leukemia also can be attributable to other complications of SCT. Therefore, this disease might be missed or interpreted as recurrence of the initial disease. It is important for hematopathologists and hematologists to be aware of this entity in order to guide treatment strategies. We propose a diagnostic algorithm for the differential diagnoses of T-LGL leukemia and T-LGL proliferation after SCT ( Figure 5 ). The most important distinguishing features are TCR gene rearrangements and STAT3 mutation status. 
